CG Oncology widens bladder cancer ambitions after late-stage recurrence data
CG Oncology is moving toward a broader regulatory push after late-stage data showed cretostimogene sharply reduced recurrence risk in a subset of patients with non-muscle invasive bladder cancer after surgery. The company said the phase 3 findings support an expanded plan for U.S. filings and strengthen the case for the drug across a wider segment of bladder cancer that has not responded adequately to Bacillus Calmette-Guérin, the long-standing standard in this disease.
The newest readout comes from PIVOT-006, a 367-patient study in intermediate-risk patients with high-grade Ta NMIBC. Over 17 months, cretostimogene reduced the risk of tumor recurrence by 68% and did so without new safety signals. In bladder cancer, recurrence after resection is not a minor inconvenience; it is the central clinical problem. Even when disease is non-muscle invasive, repeated recurrences can lead to repeated procedures, repeated anesthesia, cumulative morbidity, and eventually escalation to more aggressive treatment.
A single intravesical therapy that lowers that recurrence burden while preserving tolerability carries obvious appeal. The therapy is an oncolytic virus-based immunotherapy administered directly into the bladder after surgery, a route that is designed to concentrate activity where residual malignant cells are most likely to remain while limiting systemic exposure. In practical terms, that local delivery strategy matters because NMIBC treatment is as much about controlling microscopic residual disease as it is about removing an obvious tumor.
Recurrence-free survival becomes the center of gravity in NMIBC
The clinical logic behind these data is straightforward. After transurethral resection, microscopic tumor cells can persist in the urothelium, seed new papillary growth, or re-emerge from fields already primed for malignant change. A treatment that stimulates an antitumor immune response directly in the bladder may help clear those residual cells before they re-establish visible disease.
The company described the reduction in recurrence as unprecedented and unparalleled, and that language reflects how little margin exists in NMIBC between disease control and serial relapse. The most immediate consequence of the PIVOT-006 readout is not theoretical market expansion; it is the possibility that more patients with high-grade papillary disease could avoid early recurrence after resection.
The safety profile also matters. CG Oncology said no new safety signals emerged, an important point in a setting where the therapeutic bar is high and many patients are otherwise clinically stable after surgery. In bladder cancer, a treatment can fail not only by lacking efficacy, but also by becoming too difficult to tolerate for a population that often needs repeated intravesical therapy over time. A clean safety readout strengthens the argument for adopting a therapy early in the disease course, before the cancer becomes harder to manage.
FDA strategy now spans more of the NMIBC spectrum
CG Oncology is now preparing an expanded U.S. submission plan that reaches beyond the earlier filing framework. The company had already advanced an initial application that included patients with carcinoma in situ, with or without papillary tumors. The new plan is to broaden that filing to include patients with high-grade papillary-only disease as well, effectively covering the full range of patients with bladder cancer unresponsive to BCG, as the company defines it.
The regulatory sequencing is specific. CG Oncology now expects to complete the expanded FDA submission by the end of the first quarter of 2027. Separately, the company aims to file a second application in intermediate-risk high-grade Ta NMIBC in the second quarter of 2027. Those timelines suggest the company sees distinct but complementary opportunities: one in a broader BCG-unresponsive population and another in the intermediate-risk high-grade group where recurrence prevention is still a major unmet need.
That dual-track approach is clinically sensible. Patients with carcinoma in situ and those with papillary-only disease do not present with identical biology, but both sit within a disease continuum in which local control determines how quickly treatment choices narrow. By demonstrating activity across both high-grade and low-grade patients in PIVOT-006, cretostimogene gains a broader evidentiary base than many intravesical programs manage to secure.
Safety and convenience still shape adoption in bladder cancer
The emphasis on tolerability is not marketing polish; it is central to real-world use. Intravesical therapy depends on repeated instillation, patient adherence, and the ability to keep treatment going without triggering unacceptable urinary toxicity or systemic complications. A therapy that can improve recurrence-free survival while maintaining a favorable safety profile is more likely to fit into urologic practice than one that adds complexity without changing outcomes.
CG Oncology’s chief medical officer, Vijay Kasturi, framed the result as support for a differentiated clinical approach across the broad NMIBC spectrum. The company is also leaning on a growing body of clinical evidence around cretostimogene, which it views as one of the assets supporting a first-wave regulatory path in this disease. The new data do not settle every question, but they do sharpen the development path: one bladder-directed immunotherapy, two submission tracks, and a stronger argument that post-resection recurrence can be meaningfully delayed in patients whose disease has historically returned again and again.
For CG Oncology, the data arrive at an important commercial and clinical moment. The company went public in 2024 and has now added another late-stage dataset to a package that could shape investor confidence as much as clinician interest. The more consequential issue for urologists, however, is whether this recurrence reduction proves durable beyond the current follow-up window and whether the broader filing strategy can translate into an approval that reaches the patients most likely to benefit. The current readout supports that ambition, but regulatory review and longer-term follow-up will determine how far the drug can ultimately go in NMIBC.